SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Fidelity Private Credit Fund disclosed results of operations and financial condition as of June 30, 2026 (Q2 2026), including portfolio metrics, performance data by share class, portfolio characteristics (loan-to-value, leverage, interest coverage, distribution rate), and market commentary in its quarterly investment strategy report.
View raw filing on EDGAR →The filing discloses two executive events: Nancy Hawthorne's retirement and resignation as Trustee and Chairperson, and Patrick Coyne's election to Chairperson. While both a departure and an appointment occur, the prose centers on the appointment of Coyne to the Chairperson position as the forward-looking action taken by the Board in response to Hawthorne's departure. The appointment of a new Chairperson is material to investors as it represents a change in board leadership.
View raw filing on EDGAR →This Item 8.01 discloses the completion of TCGX Acquisition Corp.'s initial public offering on August 6, 2026, raising $86.25 million in gross proceeds from the sale of 8.625 million Class A ordinary shares at $10.00 per share, plus a concurrent private placement of 522,500 shares for $5.225 million. While the filing includes an audited balance sheet as of the IPO closing date, the core disclosure is the consummation of the IPO itself—a capital-raising event for a blank-check company. This does not fit neatly into the earnings_release, debt_issuance, or dilutive_issuance categories; it is a material capital event for a newly public SPAC that would affect a reasonable investor's assessment of the registrant's financial position and ability to pursue a business combination.
View raw filing on EDGAR →Bank of New York Mellon issued $2.5 billion in aggregate principal amount of senior medium-term notes across three tranches (2030 Floating Rate Notes, 2030 Fixed Rate/Floating Rate Notes, and 2034 Fixed Rate/Floating Rate Notes). This constitutes creation of a new direct financial obligation and is a material debt issuance event requiring 8-K disclosure under Item 2.03 (though filed under Item 8.01).
View raw filing on EDGAR →Lawrence Burian was elected as a Class II Director to the Board of Directors of Cinemark Holdings, Inc., effective immediately, to fill a vacancy. The appointment includes standard non-employee director compensation of a $95,000 base retainer and an annual restricted stock grant of $175,000.
View raw filing on EDGAR →Cinemark declared a quarterly cash dividend of $0.09 per share, payable on September 9, 2026, signaling management's confidence in the company's cash generation.
View raw filing on EDGAR →Radiant Logistics entered into an Amended and Restated Credit Agreement on August 7, 2026, establishing a $200 million syndicated revolving credit facility with a five-year term maturing August 7, 2031. The refinancing features improved pricing terms (SOFR plus 137.5-212.5 bps), an expanded $100 million accordion feature, and extended maturity, providing enhanced financial flexibility for acquisitions and capital deployment.
View raw filing on EDGAR →Charles Schwab issued $2.6 billion in aggregate principal amount of senior notes ($1.25 billion due 2032 and $1.35 billion due 2037) with net proceeds of approximately $2.582 million. This is a material creation of direct financial obligations under a Senior Indenture, clearly fitting the debt_issuance category. The magnitude and terms are material to investors assessing the registrant's capital structure and financial position.
View raw filing on EDGAR →This is a straightforward earnings release for Q2 2026 (three months ended June 30, 2026). The press release discloses net revenue of $44.1 million, operating income of $1.3 million, and net income of $84.3 million (driven by a $91.8 million non-cash gain on debt restructuring). The filing explicitly states "Beasley Broadcast Group, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026" and furnishes the press release as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures.
View raw filing on EDGAR →iAnthus disclosed Q2 2026 financial results (quarter ended June 30, 2026) via press release on August 12, 2026, reporting revenue of $35.3M, gross profit of $16.1M, net loss of $14.4M, and Adjusted EBITDA of $4.4M with sequential and year-over-year comparisons.
View raw filing on EDGAR →iAnthus obtained a $2.5 million revolving line of credit from Gotham Green Partners affiliates on August 12, 2026, bearing 12% annual interest with a June 27, 2027 maturity date, representing a new direct financial obligation to support operations and growth.
View raw filing on EDGAR →Pershing Square Inc. disclosed its second quarter 2026 financial results on August 12, 2026, via press release and earnings presentation. The disclosure includes detailed GAAP income statements, balance sheet highlights, assets under management data, and fee-related earnings metrics for the period ended June 30, 2026.
View raw filing on EDGAR →This disclosure describes a secondary offering of 12.5 million shares by Silver Lake Group (a major stockholder) at $22.20 per share, with the offering closing on August 12, 2026. While the Company itself does not sell shares or receive proceeds, the secondary offering is material to investors as it represents a significant liquidity event and potential dilution signal from a major shareholder. This does not fit the specific category of dilutive_issuance (which typically applies to new issuances by the company itself), but rather represents a secondary market transaction that is clearly financial in nature and material to the registrant's capital structure and shareholder base.
View raw filing on EDGAR →WhiteHawk Minerals entered into a Purchase and Sale Agreement on August 12, 2026 to acquire mineral and royalty interests in the Marcellus and Haynesville shale basins for $105.0 million, with closing expected September 25, 2026. The company is concurrently raising $50 million in Series E Preferred Stock equity financing to fund the acquisition.
View raw filing on EDGAR →WhiteHawk Minerals disclosed financial results for the second quarter ended June 30, 2026, via press release issued August 12, 2026, reporting revenue of $29.1 million, net loss of $39.2 million, and production of 70.0 MMcfe/d.
View raw filing on EDGAR →The 6-K discloses a grant of 15,060 warrants to employees on August 11, 2026, with an exercise price of $254.57 per share and a four-year vesting schedule (25% at one year, then 1/36th monthly). This is a compensatory arrangement for named executives and employees under the company's Articles of Association, materially affecting equity incentive arrangements and shareholder dilution.
View raw filing on EDGAR →Scilex entered into a Promissory Note establishing a $20 million uncommitted revolving line of credit with Vivasor, Inc. on August 8, 2026. This creates a new direct financial obligation and credit facility, which is the hallmark of debt_issuance. Although the facility is uncommitted and discretionary, the establishment of a $20 million credit arrangement is a material financial event requiring disclosure under Item 1.01. The related-party nature (CEO Henry Ji serves as Vivasor's CEO) and Board/Audit Committee approval underscore materiality.
View raw filing on EDGAR →Silence Therapeutics entered into an underwriting agreement on August 11, 2026 to issue and sell approximately 12.96 million ADSs at $13.50 per ADS, generating approximately $164.0 million in net proceeds (or $188.7 million if the underwriters' 30-day option to purchase up to 1.94 million additional ADSs is fully exercised). This registered public offering will dilute existing shareholders and materially affect the company's capital structure.
View raw filing on EDGAR →BioStem issued a press release on August 12, 2026 announcing financial results for Q2 2026 (three and six months ended June 30, 2026), disclosing net revenue of $7.9 million, gross profit of $4.8 million, and a GAAP net loss of $9.0 million per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial statements, guidance updates, and operational metrics material to investor assessment.
View raw filing on EDGAR →This disclosure describes a Board-approved repricing of underwater stock options held by named executive officers and other employees, reducing exercise prices from a range of $13.99–$24.59 per Share to $4.14 per Share. The repricing affects approximately 1.7 million shares and includes retention requirements designed to incentivize continued service. This is a compensatory arrangement modification under Item 5.02(e), distinct from an executive departure or appointment, and materially affects the value of equity compensation for the CEO, CMO, and CFO.
View raw filing on EDGAR →Cullinan announced that its Phase 3 REZILIENT3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis for zipalertinib in combination with chemotherapy for EGFR exon 20 insertion NSCLC, demonstrating statistically significant and clinically meaningful improvement with manageable safety. The company plans to pursue U.S. regulatory approval based on these positive results, representing a material clinical development milestone for its lead program.
View raw filing on EDGAR →The Compensation Committee approved a special, one-time performance-based stock option award to CEO Garo H. Armen consisting of 1,971,500 options with a 10-year term and complex vesting tied to stock price milestones (3x to 8x the $7.78 exercise price). This is a compensatory arrangement for a named executive officer disclosed under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →The filing discloses that Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (case number 26-10989 in the U.S. Bankruptcy Court for the District of Delaware) and announces the conclusion of a court-supervised Section 363 asset auction process. While the Item 8.01 disclosure focuses on the asset sale results ($163.55 million in cash plus up to $100 million in milestones), the foundational event is the Chapter 11 bankruptcy filing itself, which is a terminal signal materially threatening the registrant's continued existence as an independent operating company.
View raw filing on EDGAR →The filing announces the submission of a Form S-4 registration statement for a proposed business combination between SPACSphere Acquisition Corp. and Mobilewalla Holdco, Inc., with the combined entity expected to operate as Covariate, Inc. and trade on Nasdaq. This represents a material M&A activity—specifically the entry into and progression toward completion of a merger/business combination that will result in Mobilewalla becoming a publicly traded company. The disclosure explicitly states the transaction is "expected to close in the second half of 2026" and requires shareholder approval, making it a significant capital event material to investors.
View raw filing on EDGAR →This press release announces a $9.0 million strategic investment by ADATA Technology into 4Divinity, GCL's publishing subsidiary, bringing total ADATA investments to $32.0 million since December 2025. The investment values 4Divinity at $350 million and is intended to fund acquisition of game titles and platform advancement. While this represents a material capital infusion and valuation event for a significant subsidiary, it does not fit the specific categories of debt issuance, dilutive equity issuance to GCL shareholders, or M&A activity (no change of control disclosed). It is best classified as a material financial event involving subsidiary capitalization and strategic partnership expansion.
View raw filing on EDGAR →This is a formal earnings release dated August 12, 2026, disclosing Valens Semiconductor's Q2 2026 financial results (revenue of $18.1 million, gross margin of 61.5% GAAP, net loss of $8.1 million) and raising full-year 2026 revenue guidance to $78.0–$81.0 million. The document includes detailed financial statements, segment performance, and forward-looking guidance, all hallmarks of a quarterly earnings announcement. Material to investors as it affects assessment of the company's financial performance and outlook.
View raw filing on EDGAR →T1 Energy issued a press release on August 12, 2026 announcing Q2 2026 financial results, disclosing net sales of $250.1 million, net loss from continuing operations of $(36.9) million, and Adjusted EBITDA of $10.7 million, accompanied by an earnings call presentation.
View raw filing on EDGAR →Jumia entered into a Subscription Agreement with the International Finance Corporation (IFC) to issue 9,057,970 new ordinary bearer shares (as ADSs) for approximately US$25 million, and concurrent Share Purchase Agreements with other investors (including Axian) for 4,528,983 new ADSs for approximately US$25 million, totaling US$50 million in gross proceeds. The shares are being issued outside the registered offering framework under Securities Act exemptions, and certain investors have been granted registration rights. This is a material unregistered equity issuance that dilutes existing shareholders.
View raw filing on EDGAR →This press release announces regulatory milestones for two Phase III drug candidates: Namodenoson's FDA Fast Track and Orphan Drug designations for hepatocellular carcinoma, and Piclidenoson's advancement in Phase III development for psoriasis. While these are significant clinical and regulatory achievements that would inform a reasonable investor's assessment of the company's pipeline maturity and approval pathways, they do not constitute a discrete event type (such as earnings, M&A, or executive changes) but rather represent operational progress in clinical development. The disclosure emphasizes "established regulatory pathways" and "advanced regulatory status" as strategic achievements, making this an operational/clinical milestone rather than a financial or governance event.
View raw filing on EDGAR →This is a press release dated August 12, 2026, announcing RADCOM's second quarter 2026 financial results. The exhibit discloses quarterly revenues ($11.8 million), operating results (GAAP operating loss of $3.8 million), net loss ($3.1 million), and six-month results, along with consolidated financial statements. The disclosure is material as it reports a significant 33.4% year-over-year revenue decline and shift from profitability to losses, which would affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →This is a press release disclosing Q2 2026 financial results (net loss of $7.8M for three months, $15.6M for six months) alongside material corporate developments including FDA NDA acceptance with Priority Review, a $320M partnership with Azurity Pharmaceuticals, and a PDUFA goal date of November 28, 2026. While the release bundles multiple material events, the primary disclosure vehicle is the earnings announcement with accompanying financial statements (balance sheet and income statement), making this an earnings_release. The material partnership and regulatory milestones are disclosed as corporate highlights within the earnings context.
View raw filing on EDGAR →Kornit Digital reported Q2 2026 financial results on August 12, 2026, with revenues of $55.3M (+11% YoY), Adjusted EBITDA of $0.3M, and ARR of $33.8M (+79% YoY), along with forward guidance for Q3 and H2 2026. The disclosure includes consolidated financial statements, GAAP to non-GAAP reconciliations, and supporting presentation slides for the earnings conference call.
View raw filing on EDGAR →The press release announces entry into a five-year networking integration technical services agreement with a regional provider in Indonesia, valued at US$10.0 million in fixed fees, as part of the Company's AI computing infrastructure deployment. This is a material operational and strategic milestone for a co-primary business line launched in February 2026. While the agreement itself is not a customer revenue contract and carries significant execution risks, it represents a substantive infrastructure commitment supporting the Company's stated strategic pivot toward AI computing as a principal business alongside its whisky operations.
View raw filing on EDGAR →This is a standard earnings release disclosing Q2 2026 financial results for Unicycive Therapeutics. The filing explicitly states under Item 2.02 that the company "issued a press release announcing its financial results for the second quarter ended June 30, 2026" with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement) and per-share metrics (net loss of $(0.06) per share), along with a business update regarding the company's lead drug candidate OLC. This is a material disclosure affecting investor assessment of the registrant's financial condition and operational progress.
View raw filing on EDGAR →The filing discloses the appointment of Jonathan Peri, Ph.D., J.D. as an independent director to Citius Oncology's Board, effective August 10, 2026, expanding the Board to nine members. The Board determined Dr. Peri qualifies as independent under Nasdaq listing standards and will be compensated under the Company's director compensation program. This is a clear executive/director appointment event under Item 5.02(d).
View raw filing on EDGAR →CID Holdco received a Staff Determination from Nasdaq on August 6, 2026, to delist the Company's common stock pursuant to Nasdaq Listing Rule 5450(b)(2)(A) due to failure to maintain the minimum Market Value of Listed Securities ($50 million) requirement. The Company plans to appeal the determination by requesting a hearing before a Nasdaq Hearings Panel by August 13, 2026.
View raw filing on EDGAR →This is a press release announcing IceCure's financial results for the first half of 2026, disclosing revenue of $1.8 million (45% year-over-year growth), gross profit of $548,000, and a net loss of $8.775 million. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, and cash flows) for the six-month period ended June 30, 2026, along with operational highlights such as 70% growth in active installed base and $8.5 million in capital raised. This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →LiveOne issued a press release on August 12, 2026 announcing Q1 Fiscal 2027 financial results for the quarter ended June 30, 2026, including revenue of $19.4M and adjusted EBITDA of $4.3M (a $6.1M year-over-year improvement), along with consolidated financial statements and non-GAAP reconciliations.
View raw filing on EDGAR →PodcastOne disclosed its Q1 Fiscal 2027 financial results on August 12, 2026, via press release, reporting revenue of $16.1M (up 8% YoY), Adjusted EBITDA of $1.6M (up 172% YoY), and a net loss of $1.6M, along with detailed consolidated financial statements.
View raw filing on EDGAR →This press release announces the grant of a Japanese patent by NeuroThera Labs (SciSparc's majority-owned subsidiary) for a proprietary pharmaceutical combination of 4-aminophenol derivatives and N-acylethanolamines. The disclosure emphasizes that this patent "strengthens NeuroThera's expanding intellectual property portfolio" and represents "an important strategic milestone" as the company advances its therapeutic platforms. While not a discrete M&A, financing, or governance event, the patent grant is a material operational and strategic milestone that would affect a reasonable investor's assessment of the company's intellectual property protection and competitive position in its drug development programs.
View raw filing on EDGAR →CleanCore priced a public offering of 275.8 million shares of common stock, 124.2 million pre-funded warrants, and 400 million investor warrants for approximately $100 million in gross proceeds. The offering includes substantial warrant issuances (524.2 million warrants total) that are immediately or near-immediately exercisable, creating significant dilution to existing shareholders. The 90-day lock-up on new issuances and 180-day restriction on variable rate transactions further confirm the dilutive nature of this capital raise. This is a material equity issuance that would substantially affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →The filing discloses Spectral AI's financial results for Q2 2026 (quarter ended June 30, 2026), including revenue of $3.5 million, net loss of $(4.2) million, and cash position of $14.0 million. The press release (Exhibit 99.1) provides a comprehensive earnings announcement with detailed financial metrics, business highlights including FDA clearance for the DeepView System, and forward guidance of $18.5 million revenue for 2026. This is a standard quarterly earnings release disclosed via Item 2.02 and Item 7.01.
View raw filing on EDGAR →The press release announces that Hongli Group has regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share) after previously receiving a deficiency notice on July 2, 2026. While the company has now cured the deficiency, the disclosure documents a material delisting risk event—the company was out of compliance with continued listing standards and faced potential delisting. This is material to investors as it directly affects the company's listing status and trading availability.
View raw filing on EDGAR →Longeveron issued a press release on August 12, 2026 announcing financial and operating results for the three and six months ended June 30, 2026, including detailed quarterly financial metrics (revenues, expenses, net loss, cash position) and business updates. The disclosure is a standard quarterly earnings announcement with financial results and operational highlights, which is the core purpose of Item 2.02 disclosures.
View raw filing on EDGAR →Toppoint Holdings disclosed second quarter 2026 financial results via press release, reporting revenue of $4.6 million (up 17% year-over-year), gross margin improvement to 8%, and net loss narrowing 80% to $306,711.
View raw filing on EDGAR →This is a straightforward earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The filing explicitly states "On August 12, 2026, Gaxos.ai Inc. announced financial results for the quarter ended June 30, 2026" under Item 2.02, with the press release furnished as Exhibit 99.1. The press release reports record consolidated revenue of $2.46 million (up 35.8% sequentially and 1,337% year-over-year), GAAP net income of $241,056, and other key financial metrics. This is material to investors as it discloses the company's operating and financial performance.
View raw filing on EDGAR →This 6-K furnishes unaudited interim consolidated financial statements (balance sheet, statements of operations and comprehensive loss, cash flows, and changes in shareholders' equity) for the six months ended June 30, 2026, along with comparative periods. The document is explicitly labeled "UNAUDITED INTERIM CONSOLIDATED FINANCIAL DATA" and presents a complete set of interim financial statements covering a half-year period, not a discrete event or earnings press release. This is a periodic interim financial report, the foreign-issuer equivalent of a 10-Q.
View raw filing on EDGAR →Blackstone Secured Lending Fund entered into a Fifth Amendment to its senior secured credit agreement on August 10, 2026, modifying the terms of its $2.425 billion credit facility. The amendment extends borrowing periods and maturity dates, adjusts aggregate commitments to $2.375 billion, and resets financial covenants, materially affecting the Company's borrowing capacity and leverage position.
View raw filing on EDGAR →Myseum.AI announced the launch of a new user acquisition platform partnering with 34 non-profit organizations (including Special Olympics, YMCA, Junior Achievement) representing 1.6+ million members. The disclosure emphasizes this as a "scalable, lower-cost channel for acquiring engaged, active users" and a "meaningful driver of both user acquisition and revenue," directly addressing the company's stated top priorities. This is a material operational and strategic business development—a significant partnership and go-to-market initiative—that does not fit the specific operational categories (workforce reduction, material contract, etc.) but clearly warrants disclosure as a material business event affecting investor assessment of growth strategy and revenue prospects.
View raw filing on EDGAR →The filing discloses Q2 2026 financial results for the period ended June 30, 2026, including revenue ($124,914), operating expenses, net loss ($2.9 million), and cash position ($27.7 million). The press release, furnished as Exhibit 99.1, is the primary disclosure vehicle for these quarterly financial results, which is the hallmark of an earnings release under Item 2.02. While the filing also mentions going-concern alleviation and a private placement, the core Item 2.02 disclosure centers on the quarterly financial results announcement.
View raw filing on EDGAR →